Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00104364
Status:
COMPLETED
Last Update Posted:
2015-01-30
First Post:
2005-02-25
Brief Title:
A Study of MK0731 in Patients With Advanced Solid Tumors 0731-002COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
An Open-label Dose Escalation Phase III Trial of a KSP Inhibitor Given as a Constant 24-Hour Infusion in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study MK0731 in patients with recurrent or non-responsive solid tumors or cancers for which standard therapy does not exist
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time Full information is available to trial participants
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time Full information is available to trial participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_004 | None | None | None |